Karyopharm Therapeutics's total assets for Q2 2025 were $104.88M, a decrease of -17.88% from the previous quarter. KPTI total liabilities were $343.81M for the fiscal quarter, a 3.06% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.